iwild casino bonus ohne einzahlung
None
Revealed: Saudi Arabia accused of modifying official Cop29 negotiating text( MENAFN - Investor Brand Network) Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently received additional written guidance and a roadmap from the U.S. Food and Drug Administration's (“FDA”) Division of Neurology 1 regarding a potential accelerated approval pathway for lead drug candidate CNM-Au8 in ALS.“The FDA guidance on a potential path to meet the regulatory standard for substantial evidence of effectiveness supporting accelerated approval came following an in-person Nov. 1 Type C meeting with the DN1 where the company presented additional clinical trial data and analyses. The FDA recommended that Clene leverage additional Neurofilament Light ('NfL') data from its three Expanded Access Programs ('EAPs') to support earlier findings,” reads an article discussing the guidance. “Together with the survival and supportive biomarker data generated thus far, the drug's benign safety profile, and the emerging EAP NfL data, we look forward to continued discussions with the Agency,” said Clene's CEO and President, Rob Etherington.“Clene plans to include the additional data in an NDA submission under the accelerated approval pathway in mid-2025. We remain dedicated to the ALS community and honored to help critically ill patients and their families.” To view the full article, visit About Clene Inc. Clene (along with its subsidiaries,“Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit . NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company's newsroom at About BioMedWire BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer BioMedWire San Francisco, CA 415.949.5050 Office [email protected] BioMedWire is powered by IBN MENAFN26122024000224011066ID1109033808 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Teen sensation Sam Konstas says he is up for the challenge of playing Test cricket this summer, believing he is in the right headspace to debut for Australia. Konstas catapulted back into the public spotlight on Sunday when he smashed a 90-ball century against a Test-level Indian attack for the Prime Minister's XI in Canberra. The runs showed the 19-year-old is clearly a step above, with only one other batsman in the PM's XI top or middle order passing five runs. He is also a keen meditator before games, and moves quickly to the wicket in a statement of intent at the start of his innings. "I don't get too fazed about (the hype)," Konstas said. "It's about being in the present and being the best version of myself, and then hopefully let the result take care of itself." Likewise, Konstas said he had not been too down about missing out on Test selection for the start of the summer. "I feel like it's all part of the journey," he said. "Unfortunately I didn't get the runs that I would have liked. "But I've been reflecting on how I could have done better and challenging how they got me out and tactics they used."
As lawmakers in Concord prepare to elect a speaker of the House on Wednesday, a Republican challenger to GOP Speaker Sherman Packard is emerging. State Rep. Kim Rice is back in the House after a one-term hiatus, and it's possible she could take the gavel with a bipartisan coalition. When contacted by News 9, Rice declined to comment on challenging Packard, a fellow Republican and the incumbent speaker. If Rice is going to pull off an upset, she will need help from Democrats. >> Download the free WMUR app to get updates on the go: Apple | Google Play Greenwood scores his 20th Ligue 1 goal in just 14 matches, only Ibrahimovic and Neymar have done it quicker this century
Florian Flömpung, a promising young full-back from Germany, has been on Liverpool's radar for quite some time now. Known for his versatility and attacking prowess, Flömpung has impressed scouts with his performances for his current club and the German national team. Liverpool see him as a potential long-term replacement for Alexander-Arnold, should the Englishman decide to seek a new challenge abroad.
Wu Yingjie's expulsion from the party marks a significant development in the ongoing anti-corruption campaign in China. The case has once again demonstrated the CPC's unwavering commitment to fighting corruption at all levels of the party and government. The party's zero-tolerance stance towards corruption sends a clear message that no one, regardless of their position or authority, is above the law.Cristiano Ronaldo, one of the greatest footballers of all time, made headlines recently for a surprising move – appearing on a popular TV variety show. The show, which is known for its fun and light-hearted atmosphere, provided a unique opportunity for fans to see a different side of the football superstar. During the episode, Ronaldo engaged in various challenges, shared personal anecdotes, and even showcased his sense of humor.
NVIDIA, a leading American technology company known for its graphics processing units (GPUs), is facing the possibility of a substantial fine amidst increasing regulatory scrutiny in China. The company disclosed in its recent earnings report that the China mainland market accounted for 15% of its total revenue in the third quarter. This significant contribution highlights the importance of the Chinese market to NVIDIA's overall financial performance but also raises concerns about potential regulatory challenges.In conclusion, while injuries have been a major setback for Manchester United this season, the imminent return of players like Lindelof provides a glimmer of hope for the club's supporters. With the team's depth being tested, Solskjaer will be looking for his players to step up and deliver as the business end of the season approaches.Online space for teens needed despite social media ban
In conclusion, Sangio's journey towards embracing selfishness on the field serves as a powerful reminder that success in sports, like in life, often requires a willingness to break free from conventional norms and forge your own path. By daring to be different and trusting in his own abilities, Sangio is setting himself apart as a player to watch and a force to be reckoned with in the world of football.SAN DIEGO , Nov. 23, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Bumble Inc. (NASDAQ: BMBL) securities between November 7, 2023 and August 7, 2024 , both dates inclusive (the "Class Period"), have until this upcoming Monday, November 25, 2024 to seek appointment as lead plaintiff of the Bumble class action lawsuit. Captioned Holzer v. Bumble Inc. , No. 24-cv-01131 (W.D. Tex.), the Bumble class action lawsuit charges Bumble as well as certain of Bumble's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Bumble class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-bumble-class-action-lawsuit-bmbl.html You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com . CASE ALLEGATIONS : Bumble provides online dating and social networking. The Bumble class action lawsuit alleges that defendants created the false impression that they possessed reliable information pertaining to Bumble's consumer market, resulting in defendants' confidence that the relaunch of the Bumble app, its associated marketing campaign, and the connected revamp of Bumble's Premium Plus subscription tier would boost Bumble's growth through an expanded user base and increased revenue per paid user in the second half of the year. The Bumble class action further alleges that on February 27, 2024 Bumble reported disappointing fourth quarter fiscal 2023 results despite the recent launch of the Premium Plus subscription tier in December 2022. Bumble's management further announced that the Premium Plus tier would be revamped as part of the planned Bumble app relaunch as it did not have a clear enough market fit at launch and, as a result, Bumble lowered its guidance for full year 2024, according to the complaint. On this news, Bumble's stock price declined nearly 15%, according to the Bumble class action lawsuit. The Bumble class action also alleges that on August 7, 2024 Bumble announced mixed second quarter 2024 results, disclosing that the app relaunch was not going to plan and that Bumble would need to "reset" its outlook and "rebalance Bumble subscription tiers," including a pause in the revamp of the poorly received Premium Plus tier. Bumble also cut its fiscal year guidance for a second time, according to the complaint. On this news, Bumble's stock price declined more than 29%, according to the Bumble class action lawsuit. THE LEAD PLAINTIFF PROCESS : The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or otherwise acquired Bumble securities during the Class Period to seek appointment as lead plaintiff in the Bumble class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Bumble class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Bumble class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Bumble class action lawsuit. ABOUT ROBBINS GELLER : Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities- fraud .html Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@rgrdlaw.com View original content to download multimedia: https://www.prnewswire.com/news-releases/monday-investor-deadline-bumble-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit---bmbl-302310757.html SOURCE Robbins Geller Rudman & Dowd LLP